Ymmunobio AG is a preclinical stage biotechnology company developing two first in class assets in GI cancer.

Products, services, technology

YB-800, an ADC candidate with a new target receptor

YB-200, an immune agonist targeting CEACAM1 (orphan drug designation in HCC granted by FDA in Feb 2023)

Cooperation possibilities

Open to collaboration with companies who specialize in ADCs

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in